The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay

Haemophilia

Volumn 17, Issue 5, 2011, Pages

  Pouplard, C ^a   Caron, C ^b   Aillaud, M F ^c   Ternisien, C ^d   Desconclois, C ^e   Dubanchet, A ^f   Sobas, F ^g  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIV LILLE   (France)

^c TIMONE HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e BICÊTRE HOSPITAL   (France)

^f PFIZER INC   (United States)

^g EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Assay discrepancies; Chromogenic assay; Factor VIII; One stage clotting assay; Recombinant B domain deleted FVIII

Indexed keywords

BLOOD CLOTTING FACTOR 8C; CHROMOGENIC SUBSTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; BLOOD LEVEL; CHROMOGENIC SUBSTRATE ASSAY; DRUG EFFICACY; HEMOPHILIA A; HUMAN; IMMUNOASSAY; MULTICENTER STUDY; ONE STAGE CLOTTING ASSAY; PRIORITY JOURNAL;

BIOLOGICAL ASSAY; BLOOD COAGULATION TESTS; CHROMOGENIC COMPOUNDS; FACTOR VIII; FRANCE; HEMATOLOGIC TESTS; HEMOPHILIA A; HUMANS; INFUSIONS, INTRAVENOUS; PEPTIDE FRAGMENTS; REFERENCE STANDARDS;

EID: 80051963635     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02523.x     Document Type: Article

References (12)

1. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002; 28: 247-56.
2. Mikaelsson M, Oswaldsson U. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. Semin Thromb Hemost 2002; 28: 257-64.
3. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
4. Caron C, Dautzenberg MD, Delahousse B et al. A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution. Haemophilia 2002; 8: 639-43.
5. Ingerslev J, Jankowski MA, Weston SB, Charles LA. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost 2004; 2: 623-8.
6. Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gringeri A, Mannucci PM. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost 2003; 1: 2283-9.
7. Santoro C, Iorio A, Ferrante F et al. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII). Haemophilia 2009; 15: 779-87.
8. Raut S, Bevan S, Hubbard AR, Sands D, Barrowcliffe TW. A collaborative study to establish the 7th International Standard for Factor VIII Concentrate. J Thromb Haemost 2005; 3: 119-26.
9. Meijer P, de Maat MP, Kluft C, Haverkate F, van Houwelingen HC. Long-term analytical performance of hemostasis field methods as assessed by evaluation of the results of an external quality assessment program for antithrombin. Clin Chem 2002; 48: 1011-5.
10. Sobas F, Benattar N, Bellisario A et al. Impact of quality control matrix effect: application to the calculation of uncertainty of measurement in one-stage clotting factor VIII assay. Blood Coagul Fibrinolysis 2010; 21: 498-501.
11. Hubbard AR, Sands D, Sandberg E, Seitz R, Barrowcliffe TW. A multi-centre collaborative study on the potency estimation of ReFacto. Thromb Haemost 2003; 90: 1088-93.
12. Raut S, Sands D, Heath AB, Barrowcliffe TW. Variability in factor VIII concentrate measurement: results from SSC field collaborative studies. J Thromb Haemost 2003; 1: 1927-34.